TAPO in first-line osimertinib therapy and continuation of osimertinib.

Chihiro Mimura,Kazumi Kaneshiro,Shodai Fujimoto,Ryota Dokuni,Natsuhiko Iwamoto,Kanoko Matsumura,Yukihisa Hatakeyama, Yuko Kono,Motoko Tachihara

Thoracic cancer（2023）

引用 0|浏览2

暂无评分

摘要

This study showed that grade 1 D-ILD might include TAPO and that patients with TAPO might have good PFS. We need to consider the possibility of osimertinib continuation when lung opacities appear.

查看译文

关键词

NSCLC,interstitial lung disease,lung cancer,transient asymptomatic pulmonary opacity (TAPO)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要